India, April 28 -- Axogen, Inc. (AXGN) on Tuesday reported financial results for the first quarter ended March 31, 2026, reflecting 26.6% revenue growth. In addition, the firm raised its full-year 2026 revenue guidance.
Following the news, AXGN is surging 9.02%, at $42.94.
Axogen develops and commercialises technologies for peripheral nerve regeneration and repair.
For the first quarter of 2026, net loss expanded to $19.58 million, or $0.38 per share, compared to $3.83 million, or $0.08 per share, in the prior year.
Adjusted net income was $4.1 million or $0.07 per share, compared to an adjusted net loss of $0.9 million, or $0.02 per share a year ago.
Revenue increased 26.6% to $61.46 million from $48.56 million in the prior year.
goo...